The mass spectrometry proteomics data have been uploaded into ProteomeXchange PRIDE database (with identifier PXD001443 and and [10.6019/PXD001443](http://dx.doi.org/10.6019/PXD001443)).

Introduction {#sec001}
============

Methamphetamine is an addictive psychostimulant drug of abuse, with an estimated global annual prevalence of 0.7% and reports of increasing use \[[@pone.0139829.ref001]\], heightening the need for better understanding of long-term changes in the brain following repeated use. Methamphetamine causes extensive protein expression changes in the rodent and monkey brain, notably to dopaminergic markers of the mesolimbic system \[[@pone.0139829.ref002],[@pone.0139829.ref003]\].

Many studies use experimenter-administered methamphetamine "binge" treatments that deliver between 10--40 mg/kg to experimental animals in a single day \[[@pone.0139829.ref004],[@pone.0139829.ref005]\]. These studies consistently report reduced dopamine, serotonin, dopamine transporter, vesicular monoamine transporter binding and increased glial fibrillary acidic protein following binge regimens in rats, mice and monkeys \[[@pone.0139829.ref003]\]. Many of these changes occur in the striatum and can persist longer than 6 months \[[@pone.0139829.ref005]\].

In human chronic users, methamphetamine administration occurs in either consistent low-doses or high-dose binge cycles \[[@pone.0139829.ref006]\]. Methamphetamine is readily self-administered by rodents and is a method with greater face validity to experimenter-administered models \[[@pone.0139829.ref007]\]. Global protein expression changes are poorly understood as previous methamphetamine self-administration studies have focused on dopaminergic markers \[[@pone.0139829.ref007],[@pone.0139829.ref008]\], with transient or reduced effects seen compared to binge regimens.

Proteomics has been used to study the effects of multiple drugs of abuse in animal models, producing a valuable resource to further study biochemical pathways and gene/protein networks \[[@pone.0139829.ref009]\]. Using proteomics techniques, changes in energy metabolism, oxidative stress, protein modification and degradation have been shown in the rat brain following methamphetamine administration \[[@pone.0139829.ref010],[@pone.0139829.ref011]\]. Previous studies using neurotoxic doses of methamphetamine (i.e. \>40 mg/kg/day) showed differential expression of proteins involved in oxidative stress, mitochondrial dysfunction, cell cytoskeleton and apoptosis \[[@pone.0139829.ref010],[@pone.0139829.ref012],[@pone.0139829.ref013]\]. Mass spectrometry-based proteomics has been applied to amphetamine \[[@pone.0139829.ref014]\], cocaine \[[@pone.0139829.ref015]\] and methamphetamine \[[@pone.0139829.ref016]\] self-administration, which identified a large number of proteins that persist into abstinence. A proteomics study of rat hippocampus during amphetamine self-administration, abstinence and relapse reported over-representation of cytoskeletal proteins during abstinence suggesting the utility of these techniques to identify proteins conferring individual vulnerability to relapse \[[@pone.0139829.ref014]\].

The synaptosome is a sub-cellular fraction containing the pre-synaptic terminal and post-synaptic density \[[@pone.0139829.ref017]\], enabling the study of synaptic processes in response to drug treatments \[[@pone.0139829.ref018]\]. Synaptic plasticity occurs following repeated exposure to all drugs of abuse \[[@pone.0139829.ref019]\]; therefore, synaptic protein regulation may provide insight regarding biochemical pathways altered following repeated drug administration.

Due to limited information on protein changes following methamphetamine self-administration, we used proteomics to identify and characterise persistent protein changes in synaptosomes following methamphetamine self-administration in rats following 14 days abstinence. Investigation of neurobiological changes during abstinence are an essential step towards developing new treatment strategies for drug addiction.

Materials and Methods {#sec002}
=====================

All research was approved by the Animal Ethics Committee, Victoria University of Welligton, New Zealand (2012R34). Male Sprague-Dawley rats (Rattus norvegicus, 300--350 g) were housed individually in temperature (19--21°C) and humidity (55%) controlled hanging polycarbonate cages on a 12 hour light/dark cycle. At the start of the experiment, there were 8 control rats and 9 methamphetamine self-administration rats. Animals had ad libitum access to food and water except during self-administration. Animals were deeply anaesthetised with Ketamine (90 mg/kg, I.P.) and Xylazine (9 mg/kg, I.P.), fitted with chronic indwelling jugular catheters and assigned to control or methamphetamine self-administration groups. The study design isolated dorsal striatum (dStr) synaptosomes from control (n = 8) or methamphetamine self-administration (n = 7) rats. Proteins were subsequently extracted and analysed using LC-MS/MS, to compare between the two treatments. Synaptosomal proteins used for proteomics analysis were based on sufficient protein yield; therefore, n = 6 for each group was used.

Methamphetamine self-administration {#sec003}
-----------------------------------

At the start of the experiment, there were 8 control rats and 9 methamphetamine self-administration rats. Rats were fitted with chronic indwelling jugular catheters and assigned to control or methamphetamine self-administration groups. Rats received training for methamphetamine in standard operant chambers 5 days post-surgery (Med Associates, ENV-001, St Albans, Vermont, USA) using previously reported methods \[[@pone.0139829.ref004]\]. Active lever depression lead to a 12 s, 0.1 mL infusion of methamphetamine-HCl (BDG Synthesis, Wellington, NZ, 0.1 mg/kg/infusion) dissolved in sterile heparinised (3 U/mL) physiological saline concurrent with light illumination above the active lever. Control animals received heparinised saline infusions upon depression of the active lever. Once on a fixed ratio-5 (FR-5) schedule, rats had daily 2 hour sessions for 6 days/week for 20 days followed by 14 days abstinence \[[@pone.0139829.ref020]\]. Responses were recorded using Med Associates software (MED-PC IV, version 4.2). Rats that completed the whole experiment (control, 8; methamphetamine self-administration, 7) were euthanised, brains rapidly removed and dStr rapidly dissected using an acrylic stereotaxic brain matrixes block (Alto, AgnTho'sAB, Sweden) and coordinates from Paxinos and Watson \[[@pone.0139829.ref021]\].

Synaptosome purification {#sec004}
------------------------

Synaptosome purification was performed using methods previously described \[[@pone.0139829.ref017]\]. Briefly, Percoll (pH 7.4, GE Healthcare, Auckland, NZ) gradients were mixed with 50 mM DTT (Merck Ltd, NZ) and gradient buffer (1.28 M sucrose, 20 mM Tris, 4 mM EDTA, pH 7.4) to make 23%, 10% and 3% solutions in 10.4 mL polycarbonate tubes (Cat\# 355651, 10.4 mL, Beckman Coulter, Palo Alto, CA, USA).

The dStr from both sides of the rat brain were combined and homogenised in a glass-teflon homogeniser (10 strokes) (Wheaton Scientific, NJ, USA) in gradient buffer (9 mL/g). Homogenates were centrifuged at 1,000 x g for 10 min (4°C), the supernatant S1 was removed and diluted to 4--5 mg/mL and layered onto the 3% Percoll layer. Samples were centrifuged at 30,000 x g for 5 min at maximum speed (4°C) (Beckman Coulter Optima^TM^ L-100 XP Ultracentrifuge). The synaptosome fraction at the 23%/10% interface was removed, diluted in gradient buffer and centrifuged at 20,000 x g for 30 min (4°C). Synaptosome pellets were immediately removed and stored at -80°C until further use.

Transmission electron microscopy (TEM) {#sec005}
--------------------------------------

TEM was used to directly visualise the synaptosome preparation using a standard TEM protocol \[[@pone.0139829.ref022]\].

Glutamate release assay {#sec006}
-----------------------

The glutamate release assay was developed using previously described methods \[[@pone.0139829.ref023]\]. Briefly, dStr synaptosomes (n = 3, 0.3 mg/mL) were loaded into wells of a 96-well plate, placed into a fluorescent plate reader (Perkin Elmer EnSpire 2300) and incubated at 30°C for 3 min. NAD^+^ (1 mM), glutamate dehydrogenase (50 U/mL), and CaCl~2~ (1 mM) (Sigma-Aldrich NZ Ltd, Auckland) were added and baseline fluorescent recordings (excitation/emission, 340/460 nm) made every 2 s for 10 min. The K^+^-channel blocker, 4-aminopyridine (4-AP, 1 mM) was added and glutamate release measured for 5 min. A standard solution of 5 nmol of glutamate was added to quantify values.

Protein extraction {#sec007}
------------------

The synaptosome pellet was dissolved in lysis buffer (40 mM Tris, 7 M urea, 2 M thiourea, 4% w/v CHAPS, and 1% protease inhibitor cocktail, P8340, Sigma-Aldrich), incubated for 60 min (4°C) with shaking, centrifuged at 15,000 x g (10 min, 4°C) and supernatants collected, protein concentrations measured using the Bradford method and stored at -20°C.

Protein digestion {#sec008}
-----------------

Protein samples were pooled into control or methamphetamine groups for LC-MS/MS as performed previously \[[@pone.0139829.ref013]\]. Briefly, proteins of equal amount (μg) from each individual were pooled (n = 6), based on sufficient protein yield from synaptosome purification for LC-MS/MS analysis A 20 μg pooled aliquot was precipitated using a Protein Precipitation Kit (Calbiochem, Germany), re-dissolved in 50 μl of buffer (8 M urea, 0.1 M Tris-HCl, pH 8.5), reduced and alkylated as previously described \[[@pone.0139829.ref024]\]. Proteins were diluted 3-fold with 100 mM Tris-HCl, pH 8.5, and digested with trypsin at an enzyme-to-substrate ratio of 1:50 (wt/wt, modified sequencing grade, Roche Diagnostics, NZ) in the presence of 1 mM CaCl~2~ for 16 hours (37°C). Formic acid was added (4% final concentration) and the resulting tryptic peptides purified with OMIX C18 tips (Agilent Technologies Inc, USA) and eluted into 10 μl of 70% ACN, 0.1% formic acid solution. The eluted peptides were dried and reconstructed in 0.1% formic acid enabling triplicate LC MS/MS analysis.

LC-MS/MS {#sec009}
--------

LC-MS/MS experiments used a Dionex UltiMate^TM^ 3000 RSLCnano system coupled to a LTQ Orbitrap XL via a nanospray ion source (Thermo Fisher Scientific, USA). Peptides were separated on a 75 μm×15 cm PepMap C18 column (3 μm, 300 Å Dionex) at a flow rate of 200 nL/min. A buffer gradient was constructed from 0.1% formic acid (Buffer A) and 0.1% formic acid in 80% ACN (Merck) (Buffer B): 2% B to start, 2--20% B for 60 min, 20--30% B for 162 min, 30--42% for 30 min, 42--65% for 60 min, 65--98% for 30 min, 98--2% for 5 min. The spray voltage was set at 1.8 kV, and the temperature of the heated capillary was set at 200°C. Full MS scan (*m*/*z* 200--1850) in profile mode was acquired in the Orbitrap with 30,000 resolution. The six most intense peptide ions from the full scan were selected and fragmented using CID (normalised collision energy, 35%; activation Q, 0.250; and activation time, 30 ms). Dynamic exclusion was enabled with the following settings: repeat count, 2; repeat duration, 30 s; exclusion list size, 500; exclusion duration, 90 s. The spectra were acquired using Xcalibur (version 2.1.0 SP1, Thermo Fisher Scientific). The LC-MS/MS experiments were performed in triplicate.

Protein identification and label-free quantitation {#sec010}
--------------------------------------------------

The LC-MS/MS spectra were searched using the *Rattus norvegicus* protein database (Uniprot Knowledgebase; 37,173 entries, downloaded November 2012) using Proteome Discoverer (PD, version 1.2.0.208, Thermo Fisher Scientific). The search allowed carboxyamidomethylation of C as a fixed modification. The dynamic side chain modifications were Oxidation on M, Carbamylation on K, Acetylation on K, Deamidation on N, Q and R, Phosphorylation on R, S, T and Y, N-terminal Carbamylation and Sulfation on S, T and Y. Missed tryptic cleavage sites was 2, mass tolerance was 0.80 Da for fragment and 10.0 ppm for parent ions in monoisotopic mode. A positive identification was a peptide with high confidence and at least one peptide at rank 1 matched to a protein with the top score. The false discovery rate (FDR) was \<1% using a decoy database strategy.

The PD search result files (.msf) were uploaded into Scaffold (version 4.3.2, Proteome Software Inc., USA) for protein identification and label-free quantitation based on spectral counts. The three LC-MS/MS technical replicates (n = 3) of each of the two groups (methamphetamine and control) were uploaded and combined in Scaffold and the total number of MS/MS spectra calculated \[[@pone.0139829.ref025]\]. The in-built spectral count normalisation function and Fischer's exact test, an appropriate test for small sample sizes \[[@pone.0139829.ref025]\] were used to calculate the fold changes and p values of protein abundances between the pooled control and methamphetamine groups. Proteins detected with ≥95% probability (Protein FDR = 0.1%) assigned by ProteinProphet \[[@pone.0139829.ref026]\] containing at least one peptide that were detected with ≥95% probability (Peptide FDR = 0.6%) assigned by PeptideProphet \[[@pone.0139829.ref027]\] were considered positive identifications and quantified. A protein was considered significantly differentially-expressed if p≤0.05 by Fisher's Exact Test \[[@pone.0139829.ref025]\] and the fold change was ≥ ±1.2 \[[@pone.0139829.ref015]\].

Bioinformatics {#sec011}
--------------

The UniProt batch retrieval tool (<http://uniprot.org/batch>) was used to create a fasta file of the identified synaptosome proteins, which was uploaded into Wolf pSORT ([http://wolfpsort.org](http://wolfpsort.org/)) to classify their subcellular localisation.

WebGestalt (<http://bioinfo.vanderbilt.edu/webgestalt>) was used for interpreting the differentially-expressed proteins in a biological context. The protein list was uploaded into WebGestalt and searched for enrichment for GO terms using the following parameters: Reference set, *Rattus norvegicus* genome; Hypergeometric test with Benjamini and Hochberg adjustment; significance level p\<0.05 and Minimum number of genes per category, 3.

Ingenuity Pathways Analysis (IPA, Ingenuity® Systems, Redwood City, CA) was used for identifying biological networks (cut-off score 20) and diseases and functions associated with the differentially-expressed proteins (p\<1.00E-03). The differentially-expressed proteins and corresponding fold changes were uploaded into the Ingenuity Knowledge database. Networks of the molecular interactions between proteins, in association with biological functions and/or diseases, were reported. Proteins are displayed with their corresponding gene names and represented as nodes, whereas biological relationship between two nodes is represented with an edge (line). All edges are supported by at least one publication from information in the Ingenuity Knowledge database. The intensity of node color indicates increased (red) or decreased (green) abundance. Nodes are displayed using various shapes that represent the functional class of the protein.

Western blotting {#sec012}
----------------

Supernatant S1 fractions (10 μg protein) from synaptosome purifications were used for Western blotting (control n = 5, methamphetamine self-administration n = 5). All of these samples were represented in the LC-MS/MS analysis and were chosen based on sufficient protein amount for Western blot analyses. One sample from each group had insufficient protein amount and therefore were excluded. Electrophoresed proteins were transferred to an Immobilon-FL PVDF membrane (Millipore, Thermo Fisher Scientific), blocked with 5% BSA and probed using anti-phosphatidylethanolamine binding protein-1 (Pebp1, 1/750 dilution, ab76582, Abcam) and anti-amphiphysin (Amph, 1/25,000 dilution, ab52646, Abcam) followed by anti-rabbit Cy5 (PA45011, GE Healthcare) and imaged using a Fujifilm FLA-5000 fluorescent scanner. Membranes were re-probed and normalised to α-tubulin (ab18251, Abcam). One-tailed t-tests were used to identify significant changes between control and methamphetamine groups (p\<0.05).

Results {#sec013}
=======

Methamphetamine self-administration {#sec014}
-----------------------------------

The acquisition rate for stable methamphetamine responding was 8/9 and one of the control rats lost catheter patency before the end of the experiment; therefore, 8 methamphetamine self-administration and 7 control rats completed the self-administration phase. Two-way ANOVA revealed significant effect between active and inactive lever responses \[F(1,266) = 24.68, p = 0.0002\], with significant effect over the 20 sessions \[F(19,266) = 2.21, p = 0.003\]. There was significant interaction between lever and time \[F(19,266) = 2.12, p = 0.0047\] ([Fig 1A](#pone.0139829.g001){ref-type="fig"}).

![Methamphetamine self-administration.\
Methamphetamine self-administration lever responses showing preference for the active lever (A). Rat weight during the self-administration study (B). Methamphetamine self-administration rats (n = 8) gained less weight than controls (n = 7) with significantly reduced body weight from day 10 (\*p\<0.05, \*\*p\<0.01, t-test).](pone.0139829.g001){#pone.0139829.g001}

Rats did not display escalation of drug intake and total methamphetamine intake across the 30 days of self-administration was 12.5±0.89 mg (1.5±0.2 mg/kg/day). The control group did not develop preference for the active lever over the inactive lever.

Methamphetamine-exposed rats gained weight slower than controls during the study ([Fig 1B](#pone.0139829.g001){ref-type="fig"}). Two-way ANOVA showed significant effect of treatment between control and methamphetamine \[F(1,396) = 8.02, p = 0.0163\] over the course of the study \[F(36,396) = 91.66, p\<0.0001\]. There was also significant interaction between treatment and time \[F(36,396) = 8.26, p\<0.0001\]. Student's t-test showed that body weight was significantly different between control and methamphetamine from day 10 (p\<0.05).

Synaptosome purification {#sec015}
------------------------

We utilised synaptosomal proteomics to identify changes in synaptic proteins following methamphetamine exposure. Synaptosomal proteomics has been successfully used to study ischaemic brain injury \[[@pone.0139829.ref028]\] and oxidative stress \[[@pone.0139829.ref029]\]. Synaptosomes imaged using TEM revealed diameters of 0.5--1 μm with visible mitochondria, synaptic vesicles and post-synaptic density ([Fig 2A](#pone.0139829.g002){ref-type="fig"}). A glutamate release assay ([Fig 2B](#pone.0139829.g002){ref-type="fig"}) showed that synaptosomes released glutamate in response to 4-AP, demonstrating synaptosomes used for proteomics analysis have maintained membrane integrity and synaptic function. Purified tissue fractions from each group of animals was pooled before being subjected to proteomics analysis of 3 technical replicates using LC-MS/MS.

![Synaptosome validation.\
TEM image of synaptosomes **(**A). Synaptosomes have 0.5--1 mm diameters, contain 1--2 mitochondria (arrowheads) and have many synaptic vesicles (solid arrows). There is also evidence of post-synaptic density attached to the pre-synaptic terminals (dashed arrow). Glutamate is released from dStr synaptosomes in response to the K^+^ channel blocker, 4-AP, confirming the presence of functional synaptosomes (B).](pone.0139829.g002){#pone.0139829.g002}

Protein identification of synaptosome samples {#sec016}
---------------------------------------------

A total of 423 (control) and 441 (methamphetamine) proteins were unambiguously identified in the synaptosome samples ([S1 Table](#pone.0139829.s004){ref-type="supplementary-material"}). The datasets are available at ProteomeXchange (<http://proteomecentral.proteomexchange.org/cgi/GetDataset>) with accession numbers via the PRIDE partner repository \[[@pone.0139829.ref030]\] with the dataset identifier PXD001443 and DOI [10.6019/PXD001443](http://dx.doi.org/10.6019/PXD001443).

Of these, 406 were common to both sets, accounting for 92% and 96% of the overall proteins identified ([S1 Fig](#pone.0139829.s001){ref-type="supplementary-material"}), indicating high correlation between the two biological conditions. Functional analyses using Wolf pSORT showed that the composition of control and methamphetamine samples are comparable to each other ([S1 Fig](#pone.0139829.s001){ref-type="supplementary-material"}) and reflected the expected composition of synaptosomes from previous reports \[[@pone.0139829.ref031]\]. For control samples, the composition was 2% cytoskeleton, 19% mitochondria, 7% membrane and 64% cytoplasm and for methamphetamine samples, the composition was 2% cytoskeleton, 18% mitochondria, 8% membrane and 66% cytoplasm.

Differentially-expressed proteins {#sec017}
---------------------------------

Label-free quantitation based on spectral counts revealed 84 differentially-expressed proteins, with 42 upregulated and 42 downregulated between control and methamphetamine ([Table 1](#pone.0139829.t001){ref-type="table"} and [S2 Table](#pone.0139829.s005){ref-type="supplementary-material"}). Most of these proteins were unambiguously identified with more than two unique peptides. We did not identify any significantly different post-translational modifications. The spectra of the three proteins, Guk1, Pdxk, Vcan, that were identified with one peptide in the control sample were manually examined and confirmed the positive identifications of these peptides ([S2 Fig](#pone.0139829.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0139829.t001

###### Differentially-expressed proteins in synaptosomes in rats following methamphetamine self-administration.

![](pone.0139829.t001){#pone.0139829.t001g}

                                                                                                                    Normalised spectral count   Unique peptides                                 
  ----------------------------------------------------------------------------------- ------------ ---------- ----- --------------------------- ----------------- ---- ---- ------------ ------ ------
  ***Mitochondria/Energy***                                                                                                                                                                     
  ATPase inhibitor, mitochondrial                                                     Atpif1       Q03344     12    0.00                        7.72              0    4    0.0052       N/A    INF
  NAD-dependent protein deacylase sirtuin-5, mitochondrial                            Sirt5        Q68FX9     34    0.00                        7.72              0    4    0.0052       N/A    INF
  Fructose-bisphosphate aldolase A                                                    Aldoa        P05065     39    240.88                      332.73            19   20   \< 0.00010   1.4    1.4
  ATP synthase subunit beta, mitochondrial                                            Atp5b        P10719     56    500.46                      384.81            25   24   \< 0.00010   0.77   -1.3
  Malate dehydrogenase, mitochondrial                                                 Mdh2         P04636     36    133.94                      98.37             12   12   0.011        0.71   -1.4
  Aconitate hydratase, mitochondrial                                                  Aco2         Q9ER34     85    125.63                      87.76             23   20   0.0055       0.71   -1.4
  Cytochrome b-c1 complex subunit 1, mitochondrial                                    Uqcrc1       QCR1       53    48.80                       30.86             11   9    0.028        0.59   -1.7
  NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial                        Ndufs1       Q66HF1     79    52.95                       32.79             15   11   0.019        0.59   -1.7
  Aspartate aminotransferase, mitochondrial                                           Got2         P00507     47    18.69                       8.68              8    3    0.041        0.5    -2.0
  10 kDa heat shock protein, mitochondrial                                            Hspe1        P26772     11    35.30                       19.29             3    3    0.02         0.5    -2.0
  Acetyl-CoA acetyltransferase, mitochondrial                                         Acat1        P17764     45    30.11                       14.47             8    6    0.013        0.5    -2.0
  NADH dehydrogenase (Ubiquinone) flavoprotein 1                                      Ndufv1       Q5XIH3     51    21.80                       7.72              6    5    0.0071       0.4    -2.5
  Dihydrolipoyl dehydrogenase, mitochondrial                                          Dld          Q6P6R2     54    21.80                       7.72              6    2    0.0071       0.4    -2.5
  Cytochrome b-c1 complex subunit Rieske, mitochondrial                               Uqcrfs1      P20788     29    11.42                       3.86              3    2    0.044        0.3    -3.3
  Mitochondrial inner membrane protein (Fragment)                                     Immt         Q3KR86     67    15.57                       4.82              4    3    0.014        0.3    -3.3
  NADH dehydrogenase (Ubiquinone) Fe-S protein 5                                      Ndufs5       B5DEL8     13    19.73                       34.72             3    5    0.029        1.8    1.8
  Triosephosphate isomerase                                                           Tpi1         P48500     27    196.24                      245.93            15   15   0.0099       1.3    1.3
  Cytochrome c oxidase subunit 2                                                      Mtco2        P00406     26    6.23                        0.00              2    0    0.012        N/A    −INF
  Aspartate aminotransferase, cytoplasmic                                             Got1         P13221     46    43.61                       21.22             10   8    0.0036       0.5    -2.0
  Guanylate kinase                                                                    Guk1         Q71RR7     22    1.04                        7.72              1    3    0.025        7.4    7.4
  Sodium/potassium-transporting ATPase subunit alpha-3                                Atp1a3       P06687     112   49.84                       19.29             13   7    0.00015      0.4    -2.5
  Glyceraldehyde-3-phosphate dehydrogenase                                            Gapdh        G3P        36    201.43                      168.78            14   15   0.049        0.77   -1.3
  ***Synaptic vesicles***                                                                                                                                                                       
  Endophilin-B2                                                                       Sh3glb2      D4A7V1     45    21.80                       48.22             3    11   0.0011       2.2    2.2
  Endophilin-A1 (fragment)                                                            Sh3gl2       F1LQ05     38    94.48                       72.33             10   10   0.05         0.77   -1.3
  Transitional endoplasmic reticulum ATPase                                           Vcp          P46462     89    52.95                       81.98             18   21   0.0078       1.5    1.5
  Amphiphysin                                                                         Amph         O08838     75    59.18                       94.52             15   20   0.0027       1.6    1.6
  Dynactin subunit 2                                                                  Dctn2        Q6AYH5     44    32.19                       49.19             10   9    0.038        1.5    1.5
  Cofilin-1                                                                           Cfl1         P45592     19    124.59                      155.27            10   13   0.038        1.2    1.2
  V-type proton ATPase subunit B, brain isoform                                       Atp6v1b2     P62815     57    248.15                      303.80            23   27   0.0095       1.2    1.2
  Protein bassoon                                                                     Bsn          G3V984     418   47.76                       68.48             17   25   0.034        1.4    1.4
  Dynamin-1                                                                           Dnm1         P21575     97    123.56                      95.48             27   27   0.033        0.77   -1.3
  Synaptotagmin-1                                                                     Syt1         P21707     47    5.19                        0.00              3    0    0.026        N/A    −INF
  Rab GDP dissociation inhibitor beta                                                 Gdi2         P50399     51    0.00                        26.04             0    2    \< 0.00010   N/A    INF
  Toll-interacting protein                                                            Tollip       A2RUW1     30    0.00                        7.72              0    3    0.0052       N/A    INF
  Protein Tom1                                                                        Tom1         Q5XI21     54    3.11                        10.61             2    4    0.039        3.4    3.4
  Isoform Glt-1A of Excitatory amino acid transporter 2                               Slc1a2       P31596-2   62    31.15                       5.79              7    3    \< 0.00010   0.2    -5.0
  ***Cytoskeleton***                                                                                                                                                                            
  A-kinase anchor protein 5                                                           Akap5        P24587     76    2.08                        8.68              2    2    0.043        4.2    4.2
  Tropomyosin alpha-3 chain                                                           Tpm3         Q63610     29    41.53                       61.72             11   15   0.029        1.5    1.5
  Tubulin alpha-4A chain                                                              Tuba4a       Q5XIF6     50    220.12                      179.38            4    4    0.023        0.77   -1.3
  Tubulin alpha-1A chain                                                              Tuba1a       P68370     50    230.50                      187.10            19   20   0.018        0.77   -1.3
  Tubulin alpha-1B chain                                                              Tuba1b       Q6P9V9     50    242.96                      192.89            2    2    0.0089       0.77   -1.3
  Actin, cytoplasmic 1                                                                Actb         P60711     42    232.58                      192.89            19   18   0.029        0.77   -1.3
  14-3-3 protein epsilon                                                              Ywhae        P62260     29    31.15                       16.40             4    4    0.022        0.5    -2.0
  14-3-3 protein eta                                                                  Ywhah        P68511     28    29.07                       14.47             3    4    0.019        0.5    -2.0
  14-3-3 protein theta                                                                Ywhaq        P68255     28    18.69                       4.82              4    3    0.0032       0.3    -3.3
  Isoform 5 of Tropomyosin alpha-1 chain                                              Tpm1         P04692-5   28    27.00                       54.01             4    5    0.0018       2.0    2.0
  Protein Tppp                                                                        Tppp         D3ZQL7     24    70.60                       96.44             8    10   0.027        1.4    1.4
  2\',3\'-cyclic-nucleotide 3\'-phosphodiesterase                                     Cnp          P13233     47    12.46                       2.89              4    2    0.012        0.2    -5.0
  Protein Cttn                                                                        Cttn         D3ZGE6     53    15.57                       33.76             4    9    0.007        2.2    2.2
  ***Neuroprotection***                                                                                                                                                                         
  Superoxide dismutase \[Cu-Zn\]                                                      Sod1         Q6LDS4     16    45.69                       81.98             5    10   0.00085      1.8    1.8
  Oxidation resistance protein 1                                                      Oxr1         Q4V8B0     93    24.92                       40.51             8    10   0.036        1.6    1.6
  Stress-induced-phosphoprotein 1                                                     Stip1        R9PXW7     63    18.69                       37.61             7    13   0.0082       2.0    2.0
  Prohibitin                                                                          Phb          P67779     30    10.38                       1.93              3    2    0.014        0.2    -5.0
  ***Neuroplasticity***                                                                                                                                                                         
  Dihydropyrimidinase-related protein 4 (Fragment)                                    Dpysl4       Q62951     61    17.65                       32.79             8    12   0.023        1.9    1.9
  Dihydropyrimidinase-related protein 5                                               Dpysl5       Q9JHU0     62    21.80                       10.61             6    6    0.035        0.5    -2.0
  ***Cell signalling***                                                                                                                                                                         
  Calcium/calmodulin-dependent protein kinase type II subunit alpha                   Camk2a       P11275     54    125.63                      95.48             12   12   0.024        0.77   -1.3
  Protein kinase C gamma type                                                         Prkcg        P63319     78    0.00                        4.82              0    2    0.037        N/A    INF
  Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform   Ppp2r2a      P36876     52    5.19                        23.15             3    7    0.00055      4.5    4.5
  Protein phosphatase 1 regulatory subunit 1B                                         Ppp1r1b      Q6J4I0     23    27.00                       44.36             6    6    0.026        1.6    1.6
  Guanine nucleotide-binding protein subunit beta-5                                   Gnb5         P62882     39    5.19                        0.00              2    0    0.026        N/A    −INF
  MOB-like protein phocein                                                            Mob4         Q9QYW3     26    0.00                        4.82              0    3    0.037        N/A    INF
  Serine/threonine-protein kinase PAK 1                                               Pak1         P35465     61    4.15                        25.08             2    7    \< 0.00010   6.0    6.0
  RCG61894, isoform CRA_a                                                             Strn         G3V6L8     86    6.23                        20.25             3    8    0.0052       3.3    3.3
  ***Neuroconnections***                                                                                                                                                                        
  Neural cell adhesion molecule 1 (Fragment)                                          Ncam1        F1LNY3     93    9.34                        1.93              4    2    0.025        0.2    -5.0
  Neuronal cell adhesion molecule long isoform Nc17                                   Nrcam        Q6PW34     143   14.54                       5.79              6    4    0.041        0.4    -2.5
  Synapsin-1                                                                          Syn1         P09951     74    127.71                      95.48             22   19   0.018        0.71   -1.4
  Synapsin-2                                                                          Syn2         G3V733     61    90.33                       59.80             12   12   0.0076       0.71   -1.4
  Isoform 1 of SH3 and multiple ankyrin repeat domains protein 3                      Shank3       Q9JLU4-2   192   37.38                       54.97             13   18   0.042        1.5    1.5
  ***Protein folding/degradation/repair***                                                                                                                                                      
  Ubiquitin carboxyl-terminal hydrolase isozyme L1                                    Uchl1        Q00981     25    74.76                       113.80            10   10   0.0027       1.5    1.5
  Peptidyl-prolyl cis-trans isomerase A                                               Ppia         P10111     18    101.75                      130.20            9    8    0.035        1.3    1.3
  T-complex protein 1 subunit epsilon                                                 Cct5         Q68FQ0     60    5.19                        0.00              3    0    0.026        N/A    −INF
  Protein Ubqln2                                                                      Ubqln2       D4AA63     67    12.46                       26.04             4    7    0.021        2.1    2.1
  Protein-L-isoaspartate(D-aspartate) O-methyltransferase                             Pcmt1        P22062     25    22.84                       8.68              5    3    0.0086       0.4    -2.5
  ***Other***                                                                                                                                                                                   
  Phosphatidylethanolamine-binding protein 1                                          Pebp1        P31044     21    118.36                      156.24            10   15   0.013        1.3    1.3
  Nucleoside diphosphate kinase A                                                     Nme1         Q05982     17    11.42                       0.00              4    0    0.00032      N/A    −INF
  Pyridoxal kinase                                                                    Pdxk         G3V647     35    1.04                        6.75              1    4    0.044        6.5    6.5
  Serum albumin                                                                       Alb          P02770     69    0.00                        6.75              0    3    0.01         N/A    INF
  Isoform V3 of Versican core protein                                                 Vcan         Q9ERB4-2   74    3.11                        11.57             1    6    0.025        3.7    3.7
  Cysteine-rich protein 2                                                             Crip2        P36201     23    5.19                        19.29             2    4    0.0035       3.7    3.7
  Protein RGD1559864                                                                  RGD1559864   D3ZB78     41    6.23                        17.36             5    6    0.018        2.8    2.8
  Uncharacterized protein                                                             4 SV         D4A269     14    7.27                        17.36             3    4    0.033        2.4    2.4
  Carbonic anhydrase 2                                                                Ca2          P27139     29    6.23                        0.00              2    0    0.012        N/A    −INF

\*Fischer's exact test. Fold change: the ratio of normalized spectral counts between Meth and Control when the protein is upregulated in Meth, or the negative reciprocal of the above ratio when the protein is downregulated in Meth; ER: Expression ratio; INF: infinite.

Western blotting {#sec018}
----------------

Two differentially-expressed synaptic proteins, Amphiphysin (Amph) and Phosphatidylethanolamine binding protein-1 (Pebp1), detected by LC-MS/MS were chosen for validation of the quantitative LC-MS/MS data using Western blotting. These were chosen based on previous links to the literature and represented proteins important for synaptic vesicles and synapse formation. Experiments showed agreement with the LC-MS/MS results for Amph (p = 0.069, 1-tailed t-test, n = 5) and Pebp1 (p\<0.05, 1-tailed t-test, n = 5) using proteins from the supernatant S1 fraction ([Fig 3](#pone.0139829.g003){ref-type="fig"}, [Table 1](#pone.0139829.t001){ref-type="table"}), indicating the reliability of the LC-MS/MS data. Additional validation of Amph utilising dStr homogenate samples also revealed a significant increase in protein expression following methamphetamine when compared to controls (p\<0.05) (data not shown.).

![Validation of protein expression.\
Western blotting showed upregulation of phosphatidylethanolamine binding protein (\*p\<0.05, 1-tailed t-test, n = 5) and a trend towards increased amphiphysin (p = 0.069, 1-tailed t-test, n = 5). Protein expression was normalized to alpha-tubulin. Key: Amph, amphiphysin; Pebp1, phosphatidylethanolamine binding protein; α-tub, alpha tubulin.](pone.0139829.g003){#pone.0139829.g003}

Functional analysis of the differentially-expressed proteins {#sec019}
------------------------------------------------------------

The GO functions of the differentially-expressed proteins annotated with WebGestalt were, mitochondria/energy, cytoskeleton, synaptic vesicles, cell signalling, neuroplasticity, protein folding/degradation, neuroprotection and others ([Table 1](#pone.0139829.t001){ref-type="table"}). Pathways analysis of the differentially-expressed proteins using IPA revealed involvement of these proteins in molecular interaction networks, including cell-to-cell signalling and interaction, nervous system development and function, cellular assembly and organisation, cell morphology, cellular development and cellular compromise ([S3 Fig](#pone.0139829.s003){ref-type="supplementary-material"}). These networks are associated with neurological disease, microtubule dynamics and cellular protrusions ([S3 Table](#pone.0139829.s006){ref-type="supplementary-material"}). The core group of proteins participating in these networks are primarily synaptic vesicle and cytoskeletal proteins.

Discussion {#sec020}
==========

This study is the first to report the use of MS-based proteomics to examine changes in synaptic protein abundance in the dorsal striatum following methamphetamine self-administration in rats. Methamphetamine is transported into the synapse through the dopamine transporter and has extensive detrimental effects, particularly on mitochondrial function \[[@pone.0139829.ref003]\]. The dStr is important as it assumes greater control over drug addiction behaviour as drug taking becomes compulsive \[[@pone.0139829.ref032]\]. We employed subcellular fractionation to enrich for synaptosomal proteins and label-free LC-MS/MS to determine the differentially-expressed proteins following methamphetamine exposure. We applied the pooling strategy \[[@pone.0139829.ref013]\] to identify the largest changes between the two groups. We chose this strategy to reduce technical variation in the label-free quantification of the samples introduced during LC-MS/MS runs due to chromatographical drift and instrumental maintenance requirements. Each LC-MS/MS run requires approximately 6 hours and the mass spectrometer also requires weekly calibration, which interrupts the sample analysis. Because this approach limits between-animal analysis, selected proteins from individual animals were validated using Western blot analysis.

Amongst the interesting differentially-expressed proteins were Amphiphysin (Amph), Phosphatidylethanolamine binding protein-1 (Pebp1) and stress-induced phosphoprotein. Amph is a Bin-amphiphysin-Rvs (BAR) domain protein, which are a group of proteins that function to create a bend in the plasma membrane prior to vesicle fusion, and also aid in the scaffolding of synaptic vesicles \[[@pone.0139829.ref033]\]. Amph mRNA has been reported to increase following methamphetamine administration in the cerebrum and cerebellum of the rat \[[@pone.0139829.ref034]\]. The importance of Amph in the brain is exemplified by learning deficits in knockout mice \[[@pone.0139829.ref035]\], which also display defects in synaptic recycling and cognitive impairment \[[@pone.0139829.ref036]\]. Other synaptic vesicle proteins were up-regulated that have demonstrated roles in synaptic vesicle budding and fusion and acidification of vesicles, including, endophilin-B2, transitional ER ATPase and the B-subunit of V-type proton ATPase \[[@pone.0139829.ref033],[@pone.0139829.ref037],[@pone.0139829.ref038]\]. The upregulation of these proteins suggests increased synaptic vesicle production or activity and may be a consequence of altered accumulation and storage of dopamine \[[@pone.0139829.ref038]\] following repeated methamphetamine exposure.

Pebp1, a serine protease inhibitor implicated in neuronal growth, differentiation and synapse production was upregulated \[[@pone.0139829.ref039]\]. Although previous reports show downregulation with methamphetamine behavioural sensitisation \[[@pone.0139829.ref040]\] and self-administration following extinction \[[@pone.0139829.ref016]\], up-regulation following cocaine self-administration followed by 100 days abstinence has been reported \[[@pone.0139829.ref015]\]. Interestingly, our results vary from a recent publication which found reduced Pebp1 following methamphetamine self-administration and extinction training \[[@pone.0139829.ref016]\]. It is possible that this difference is due to different brain regions examined (pre-frontal cortex vs dorsal striatum), although this may also reflect the new learning of a non-reinforcer in extinction when compared with abstinence, where all association with the self-administration chamber is removed. Pebp1 may therefore represent an important response to psychostimulant self-administration persisting into abstinence. Future investigations into the signalling pathways regulating Pebp1 may help elucidate the role of Pebp1 in methamphetamine addiction and abstinence.

Proteins with known neuroprotective roles, peroxiredoxin-6, oxidation resistance protein and superoxide dismutase were upregulated along with Stip1, a protein that interacts with the prion protein PrP(C) to stimulate protein synthesis in neurons. Stress-induced phosphoprotein -PrP(C) is involved in neuroprotection and neuron plasticity \[[@pone.0139829.ref041]\] and protects astrocytes from cell death \[[@pone.0139829.ref042]\].

Rearrangement of synaptic architecture occurs during both self-administration and abstinence \[[@pone.0139829.ref043]\], and increased arborisation of viable synaptic terminals may occur during abstinence following methamphetamine \[[@pone.0139829.ref044]\]. Amphetamines increase dendritic branching in the brain due to restructuring of the cell cytoskeleton \[[@pone.0139829.ref045]\], and methamphetamine behavioural sensitisation increases synaptic density in the nucleus accumbens \[[@pone.0139829.ref043]\]. Several proteins associated with axon branching, Pak1, Cttn, Phocein, and Shank3 were up-regulated.

Cytoskeleton and associated proteins including increased cofilin-1, tubulin polymerisation-promoting protein (Tppp), Cttn and tropomyosin-α; and decreased 14-3-3 isoforms, plus tubulin and actin with methamphetamine administration were also seen. Previous studies found large decreases in tubulin with methamphetamine behavioural sensitisation \[[@pone.0139829.ref040]\], and overexpression of cytoskeletal proteins following abstinence from amphetamine self-administration \[[@pone.0139829.ref014]\]. Cofilin-1 and Tppp were upregulated with methamphetamine self-administration, which bind to actin and tubulin monomers respectively and are thus involved in cytoskeletal protein stabilisation. Little is known about Tppp, as no links with methamphetamine administration have been reported.

Mitochondrial dysfunction is a well-established consequence of methamphetamine exposure as neurons are very sensitive to reduced ATP \[[@pone.0139829.ref003]\]. Our study supports this, with differentially-expressed proteins associated with mitochondria and energy regulation.

Significance {#sec021}
------------

Our results correlate well with a previous cocaine self-administration and abstinence study with 4 of the 12 proteins (Pebp1, ATP synthase beta subunit, Malate dehydrogenase and dynamin-1) corresponding \[[@pone.0139829.ref015]\]. Our results also correspond well with previous studies of brain proteomics in rats trained for methamphetamine conditioned place preference \[[@pone.0139829.ref046]\], and methamphetamine behavioural sensitisation \[[@pone.0139829.ref040]\], which identified differentially-expressed proteins involved in cytoskeletal rearrangement, signal transduction and synaptic function. Higher dosing regimens traditionally associated with neurotoxicity, in contrast, displayed a different proteomics profile in the prefrontal cortex following methamphetamine (8x1 mg/kg), where protein degradation, energy metabolism, synaptic function and cytoskeletal rearrangement pathways were highly represented \[[@pone.0139829.ref010]\]. In addition, a further proteomics study identified differentially-expressed proteins in the striatum (14), hippocampus (12) and frontal cortex (4) following methamphetamine administration (8x15 mg/kg, 12 hours apart), with common proteins altered in the different regions \[[@pone.0139829.ref012]\].

Conclusions {#sec022}
===========

The methamphetamine self-administration model employed in this proteomics study identified changes that suggest a combination of cell stress with synaptic plasticity and neuroadaptation. The model used represents drug-taking, and in future could include compulsive drug-taking and drug-seeking models. Further studies will aim to utilise yoking controls to separate protein expression changes related to the motivational aspects of drug-taking behaviour and also to identify those important during abstinence. This study provides a number of key targets which provide useful mechanistic insight into the effects of methamphetamine on dStr synaptic proteins, which can be pursued in detail with a model of drug addiction that more accurately reflects human experience. The detailed understanding of synaptic proteins in response to drugs of addiction may also allow the identification of future therapeutic targets.

Supporting Information {#sec023}
======================

###### Protein identifications of the purified synaptosome samples of the control and methamphetamine treated rats (A). Subcellular localisation of synaptosome proteins for control and methamphetamine treated rats analysed using Wolf pSORT showing a distribution of proteins that is consistent with being synaptosomal (B).

(PDF)

###### 

Click here for additional data file.

###### Spectra for single-peptide identifications.

Spectra for single-peptide identifications shown in [Table 1](#pone.0139829.t001){ref-type="table"} and [S2 Table](#pone.0139829.s005){ref-type="supplementary-material"}.

(PDF)

###### 

Click here for additional data file.

###### Networks of differentially-expressed proteins.

Proteins shaded in green indicate down-regulation and red means up-regulation. The intensity of the shade corresponds to the degree of up (red) or down (green) regulation. Proteins in white are those identified through the Ingenuity Pathways Knowledge Base. The shapes denote the molecular class of the protein. A solid line indicates a direct molecular interaction, and a dashed line indicates an indirect molecular interaction. The cut-off score of network identification was 20. Cell-to-cell signaling and interaction, nervous system development and function and cellular assembly and organization, IPA score = 55 (A); Cell morphology, cellular assembly and organization and cellular development, IPA score = 31 (B); Cellular compromise, cell morphology, cellular assembly and organization, IPA score = 21 (C).

(PDF)

###### 

Click here for additional data file.

###### All proteins identified.

(PDF)

###### 

Click here for additional data file.

###### Differentially-expressed proteins.

(PDF)

###### 

Click here for additional data file.

###### Diseases and functions associated with the differentially expressed proteins.

(PDF)

###### 

Click here for additional data file.

###### ARRIVE Guidelines Checklist.

(PDF)

###### 

Click here for additional data file.
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